University of Leicester
Browse

Targeting the kappa opioid receptor for analgesia and antitumour effects

Version 2 2025-02-04, 16:03
Version 1 2025-01-29, 15:59
journal contribution
posted on 2025-02-04, 16:03 authored by David G Lambert, Joshua S Mincer

Kappa opioid (KOP) receptor agonists have analgesic actions in a range of models, but central side-effects can limit their utility. In addition, non-analgesic actions of opioid receptors are receiving significant research interest. A recent article reports that high KOP receptor expression in glioma tissue correlates with improved survival and that KOP receptor agonism further promotes apoptosis of glioma cells through regulation of the p38 MAPK oncogenic pathway. This suggests that KOP receptor ligands could be developed as chemotherapeutic adjuncts in addition to their use as analgesics.

History

Author affiliation

College of Life Sciences Cardiovascular Sciences

Version

  • VoR (Version of Record)

Published in

British Journal of Anaesthesia

Publisher

Elsevier BV

issn

0007-0912

eissn

1471-6771

Copyright date

2025

Notes

Editorial

Spatial coverage

England

Language

en

Deposited by

Professor David Lambert

Deposit date

2025-01-13

Usage metrics

    University of Leicester Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC